Nanobiotix SA
NBTX6.430USD
-0.370-5.44%
시장 운영 시간 （ET）시세는 15분 지연됩니다
304.81M시가총액
--P/E TTM
자세한 내용은 Nanobiotix SA 회사
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
회사 정보
종목 코드 NBTX
회사 이름Nanobiotix SA
상장일Oct 29, 2012
CEODr. Laurent Levy, Ph.D.
직원 수108
유형Depository Receipt
회계 연도 종료Oct 29
주소60 rue de Wattignies
도시PARIS
증권 거래소NASDAQ Global Select Consolidated
국가France
우편 번호75012
전화33140260470
웹사이트https://www.nanobiotix.com
종목 코드 NBTX
상장일Oct 29, 2012
CEODr. Laurent Levy, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Laurent Levy, Ph.D.
Dr. Laurent Levy, Ph.D.
Chairman of the Management Board, Chief Executive Officer, Co-Founder
Chairman of the Management Board, Chief Executive Officer, Co-Founder
--
--
Mr. Bart Van Rhijn
Mr. Bart Van Rhijn
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairwoman of the Supervisory Board
Independent Vice Chairwoman of the Supervisory Board
--
--
Ms. Anne-Juliette Hermant
Ms. Anne-Juliette Hermant
Chief People Officer, Member of the Management Board
Chief People Officer, Member of the Management Board
--
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Craig West
Mr. Craig West
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Enno Spillner
Mr. Enno Spillner
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Alain Herrera
Dr. Alain Herrera
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Louis Kayitalire, M.D.
Dr. Louis Kayitalire, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Laurent Levy, Ph.D.
Dr. Laurent Levy, Ph.D.
Chairman of the Management Board, Chief Executive Officer, Co-Founder
Chairman of the Management Board, Chief Executive Officer, Co-Founder
--
--
Mr. Bart Van Rhijn
Mr. Bart Van Rhijn
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairwoman of the Supervisory Board
Independent Vice Chairwoman of the Supervisory Board
--
--
Ms. Anne-Juliette Hermant
Ms. Anne-Juliette Hermant
Chief People Officer, Member of the Management Board
Chief People Officer, Member of the Management Board
--
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Craig West
Mr. Craig West
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Fri, May 16
마지막 업데이트: Fri, May 16
주주
주주 유형
주주
주주
비율
Johnson & Johnson Innovation-JJDC, Inc.
11.86%
Perceptive Advisors LLC
0.22%
Jane Street Capital, L.L.C.
0.02%
Geode Capital Management, L.L.C.
0.02%
Morgan Stanley & Co. International Plc
0.01%
Other
87.86%
주주
주주
비율
Johnson & Johnson Innovation-JJDC, Inc.
11.86%
Perceptive Advisors LLC
0.22%
Jane Street Capital, L.L.C.
0.02%
Geode Capital Management, L.L.C.
0.02%
Morgan Stanley & Co. International Plc
0.01%
Other
87.86%
주주 유형
주주
비율
Venture Capital
11.86%
Private Equity
0.22%
Research Firm
0.04%
Investment Advisor/Hedge Fund
0.02%
Other
87.86%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
25
5.76M
12.15%
-4.19M
2025Q1
25
5.76M
12.15%
-4.19M
2024Q4
25
6.07M
12.79%
-4.24M
2024Q3
21
6.42M
13.54%
-3.89M
2024Q2
22
9.30M
19.73%
-1.04M
2024Q1
21
9.31M
19.76%
-988.94K
2023Q4
21
9.28M
19.68%
+1.01M
2023Q3
16
4.47M
12.36%
+481.67K
2023Q2
12
3.47M
9.94%
-1.27M
2023Q1
11
3.46M
9.93%
-1.28M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Johnson & Johnson Innovation-JJDC, Inc.
5.62M
11.86%
--
--
Mar 31, 2025
Perceptive Advisors LLC
105.05K
0.22%
-161.04K
-60.52%
Mar 31, 2025
Jane Street Capital, L.L.C.
11.39K
0.02%
-11.90K
-51.09%
Mar 31, 2025
Geode Capital Management, L.L.C.
10.18K
0.02%
--
--
Mar 31, 2025
Morgan Stanley & Co. International Plc
6.10K
0.01%
+1.00K
+19.61%
Mar 31, 2025
UBS Financial Services, Inc.
3.00K
0.01%
-817.00
-21.40%
Mar 31, 2025
BofA Global Research (US)
706.00
0%
-1.71K
-70.79%
Mar 31, 2025
BNP Paribas Securities Corp. North America
661.00
0%
+661.00
--
Mar 31, 2025
Citi Investment Research (US)
241.00
0%
--
--
Mar 31, 2025
RBC Capital Markets Wealth Management
136.00
0%
+7.00
+5.43%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Biotechnology ETF
0%
iShares Biotechnology ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
